{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T17:19:17Z","timestamp":1782235157011,"version":"3.54.5"},"reference-count":42,"publisher":"eLife Sciences Publications, Ltd","license":[{"start":{"date-parts":[[2020,4,6]],"date-time":"2020-04-06T00:00:00Z","timestamp":1586131200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,4,6]],"date-time":"2020-04-06T00:00:00Z","timestamp":1586131200000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,4,6]],"date-time":"2020-04-06T00:00:00Z","timestamp":1586131200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000921","name":"European Cooperation in Science and Technology","doi-asserted-by":"publisher","award":["ADMIRE BM1301"],"award-info":[{"award-number":["ADMIRE BM1301"]}],"id":[{"id":"10.13039\/501100000921","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000921","name":"European Cooperation in Science and Technology","doi-asserted-by":"publisher","award":["ENSAT-HT 633983"],"award-info":[{"award-number":["ENSAT-HT 633983"]}],"id":[{"id":"10.13039\/501100000921","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Societa\u0300 Italiana dell\u2019Ipertensione Arteriosa"},{"name":"FORICA"},{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"publisher","award":["108 258"],"award-info":[{"award-number":["108 258"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"publisher","award":["122 504"],"award-info":[{"award-number":["122 504"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elifesciences.org"],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>\n                    The discovery of angiotensin converting enzyme-2 (ACE-2) as the receptor for SARS- CoV-2 (Severe Acute Respiratory Syndrome Coronavirus-2) has implicated the renin-angiotensin-aldosterone system in acute respiratory distress syndrome (ARDS) and respiratory failure in patients with coronavirus disease-19 (COVID-19). The angiotensin converting enzyme-1\u2013angiotensin II\u2013angiotensin AT\n                    <jats:sub>1<\/jats:sub>\n                    receptor pathway contributes to the pathophysiology of ARDS, whereas activation of the ACE-2\u2013angiotensin(1-7)-angiotensin AT\n                    <jats:sub>2<\/jats:sub>\n                    receptor and the ACE-2\u2013angiotensin(1-7)\u2013Mas receptor pathways have been shown to be protective. Here we propose and discuss therapeutic considerations how to increase soluble ACE-2 in plasma in order for ACE-2 to capture and thereby inactivate SARS-CoV-2. This could be achieved by administering recombinant soluble ACE-2. We also discuss why and how ACEIs and ARBs provide cardiovascular, renal and also pulmonary protection in SARS-CoV-2- associated ARDS. Discontinuing these medications in COVID-19 patients may therefore potentially be harmful.\n                  <\/jats:p>","DOI":"10.7554\/elife.57278","type":"journal-article","created":{"date-parts":[[2020,4,6]],"date-time":"2020-04-06T08:00:18Z","timestamp":1586160018000},"update-policy":"https:\/\/doi.org\/10.7554\/elife.57278","source":"Crossref","is-referenced-by-count":106,"title":["Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients"],"prefix":"10.7554","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7963-0931","authenticated-orcid":true,"given":"Gian Paolo","family":"Rossi","sequence":"first","affiliation":[{"name":"Hypertension Unit -Department of Medicine-DIMED, University of Padova, Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viola","family":"Sanga","sequence":"additional","affiliation":[{"name":"International PhD Program in Arterial Hypertension and Vascular Biology (ARHYVAB)- University of Padua, Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8200-4341","authenticated-orcid":true,"given":"Matthias","family":"Barton","sequence":"additional","affiliation":[{"name":"University of Z\u00fcrich, Z\u00fcrich, Switzerland"},{"name":"Andreas Gr\u00fcntzig Foundation, Z\u00fcrich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4374","published-online":{"date-parts":[[2020,4,6]]},"reference":[{"key":"bib1","volume-title":"HFSA\/ACC\/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19","author":"Bozkurt","year":"2020","unstructured":"Bozkurt B, Kovacs R, Harrington B. 2020. American College of Cardiology. HFSA\/ACC\/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19. https:\/\/www.acc.org\/latest-in-cardiology\/articles\/2020\/03\/17\/08\/59\/hfsa-acc-aha-statement-addresses-concerns-re-using-raas-antagonists-in-COVID-19."},{"key":"bib2","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1093\/eurheartj\/ehi114","article-title":"Myocardial infarction increases ACE2 expression in rat and humans","volume":"26","author":"Burrell","year":"2005","journal-title":"European Heart Journal"},{"key":"bib3","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e4260","article-title":"Risk of pneumonia associated with use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers: systematic review and meta-analysis","volume":"345","author":"Caldeira","year":"2012","journal-title":"BMJ"},{"key":"bib4","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1038\/s41374-019-0289-7","article-title":"Ang- (1-7) Treatment attenuates lipopolysaccharide-Induced early pulmonary fibrosis","volume":"99","author":"Cao","year":"2019","journal-title":"Nature"},{"key":"bib5","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.120.15082","article-title":"Renin-angiotensin system blockers and the COVID-19 pandemic: at present there is no evidence to abandon renin-angiotensin system blockers","volume":"75","author":"Danser","year":"2020","journal-title":"Hypertension"},{"key":"bib6","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.taap.2016.06.026","article-title":"Activation of angiotensin-converting enzyme 2 (ACE2) attenuates allergic airway inflammation in rat asthma model","volume":"306","author":"Dhawale","year":"2016","journal-title":"Toxicology and Applied Pharmacology"},{"key":"bib7","volume-title":"EMA Advises Continued Use of Medicines for Hypertension,\u00a0Heart or Kidney Disease During COVID-19 Pandemic","author":"European Medicines Agency","year":"2020","unstructured":"European Medicines Agency. 2020. EMA. EMA Advises Continued Use of Medicines for Hypertension,\u00a0Heart or Kidney Disease During COVID-19 Pandemic. https:\/\/www.ema.europa.eu\/en\/news\/ema-advises-continued-use-medicines-hypertension-heart-kidney-disease-during-covid-19-pandemic."},{"key":"bib8","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30116-8","article-title":"Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?","volume":"8","author":"Fang","year":"2020","journal-title":"The Lancet Respiratory Medicine"},{"key":"bib9","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1093\/eurjhf\/hft110","article-title":"Haemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial","volume":"15","author":"Greene","year":"2013","journal-title":"European Journal of Heart Failure"},{"key":"bib10","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1002\/path.1570","article-title":"Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus a first step in understanding SARS pathogenesis","volume":"203","author":"Hamming","year":"2004","journal-title":"The Journal of Pathology"},{"key":"bib11","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S0014-5793(02)03640-2","article-title":"Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme","volume":"532","author":"Harmer","year":"2002","journal-title":"FEBS Letters"},{"key":"bib12","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1128\/JVI.02202-13","article-title":"TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry driven by the severe acute respiratory syndrome coronavirus spike protein","volume":"88","author":"Heurich","year":"2014","journal-title":"Journal of Virology"},{"key":"bib13","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"bib14","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/nature03712","article-title":"Angiotensin-converting enzyme 2 protects from severe acute lung failure","volume":"436","author":"Imai","year":"2005","journal-title":"Nature"},{"key":"bib15","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1113\/expphysiol.2007.040048","article-title":"The discovery of angiotensin-converting enzyme 2 and its role in acute lung injury in mice","volume":"93","author":"Imai","year":"2008","journal-title":"Experimental Physiology"},{"key":"bib16","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1161\/01.HYP.0000124667.34652.1a","article-title":"Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors","volume":"43","author":"Ishiyama","year":"2004","journal-title":"Hypertension"},{"key":"bib17","doi-asserted-by":"publisher","first-page":"14614","DOI":"10.1128\/JVI.79.23.14614-14621.2005","article-title":"ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia","volume":"79","author":"Jia","year":"2005","journal-title":"Journal of Virology"},{"key":"bib18","doi-asserted-by":"publisher","first-page":"3506","DOI":"10.2174\/092986711796642562","article-title":"Local renin-angiotensin II systems, angiotensin-converting enzyme and its homologue ACE2: their potential role in the pathogenesis of chronic obstructive pulmonary diseases, pulmonary hypertension and acute respiratory distress syndrome","volume":"18","author":"Kaparianos","year":"2011","journal-title":"Current Medicinal Chemistry"},{"key":"bib19","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1186\/s13054-017-1823-x","article-title":"A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome","volume":"21","author":"Khan","year":"2017","journal-title":"Critical Care"},{"key":"bib20","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.22211.2","article-title":"Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China","volume":"9","author":"Kruse","year":"2020","journal-title":"F1000Research"},{"key":"bib21","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/nm1267","article-title":"A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury","volume":"11","author":"Kuba","year":"2005","journal-title":"Nature Medicine"},{"key":"bib22","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.coph.2006.03.001","article-title":"Angiotensin-converting enzyme 2 in lung diseases","volume":"6","author":"Kuba","year":"2006","journal-title":"Current Opinion in Pharmacology"},{"key":"bib23","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.phrs.2017.06.005","article-title":"The vasoprotective axes of the renin-angiotensin system: physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases","volume":"125","author":"Li","year":"2017","journal-title":"Pharmacological Research"},{"key":"bib24","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb3221","article-title":"Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV2)","volume":"6","author":"Li","year":"2020","journal-title":"Science"},{"key":"bib25","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1097\/HJH.0b013e328357a87a","article-title":"Angiotensin-converting enzyme inhibitor\/angiotensin II receptor blockers and pneumonia risk among stroke patients","volume":"30","author":"Liu","year":"2012","journal-title":"Journal of Hypertension"},{"key":"bib26","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1165\/rcmb.2012-0451OC","article-title":"Angiotensin-converting enzyme 2\/angiotensin-(1-7)\/Mas axis protects against lung fibrosis by inhibiting the MAPK\/NF-\u03baB pathway","volume":"50","author":"Meng","year":"2014","journal-title":"American Journal of Respiratory Cell and Molecular Biology"},{"key":"bib27","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1161\/01.HYP.0000237862.94083.45","article-title":"Enalapril attenuates downregulation of angiotensin-converting enzyme 2 in the late phase of ventricular dysfunction in myocardial infarcted rat","volume":"48","author":"Ocaranza","year":"2006","journal-title":"Hypertension"},{"key":"bib28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000507305","article-title":"Should COVID-19 concern nephrologists? why and to what extent? the emerging impasse of angiotensin blockade","volume":"24126","author":"Perico","year":"2020","journal-title":"Nephron"},{"key":"bib29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe2006742","article-title":"New research on possible treatments for COVID-19","volume":"382","author":"Rubin","year":"2020","journal-title":"The New England Journal of Medicine"},{"key":"bib30","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1007\/s12325-012-0049-1","article-title":"Post-stroke pneumonia prevention by angiotensin-converting enzyme inhibitors: results of a meta-analysis of five studies in Asians","volume":"29","author":"Shinohara","year":"2012","journal-title":"Advances in Therapy"},{"key":"bib31","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.coph.2017.12.002","article-title":"Targeting the renin\u2013angiotensin system as novel therapeutic strategy for pulmonary diseases","volume":"40","author":"Tan","year":"2018","journal-title":"Current Opinion in Pharmacology"},{"key":"bib32","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1056\/NEJMsr2005760","article-title":"Renin\u2013angiotensin\u2013aldosterone system inhibitors in patients with COVID-19","volume":"382","author":"Vaduganathan","year":"2020","journal-title":"New England Journal of Medicine"},{"key":"bib33","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1002\/mds.26136","article-title":"Angiotensin-converting enzyme inhibitors and bacterial pneumonia in patients with parkinson disease","volume":"30","author":"Wang","year":"2015","journal-title":"Movement Disorders"},{"key":"bib34","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1002\/path.2987","article-title":"Acute respiratory distress syndrome leads to reduced ratio of ACE\/ACE2 activities and is prevented by angiotensin-(1-7) or an angiotensin II receptor antagonist","volume":"225","author":"W\u00f6sten-van Asperen","year":"2011","journal-title":"The Journal of Pathology"},{"key":"bib35","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"Wrapp","year":"2020","journal-title":"Science"},{"key":"bib36","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s11427-020-1637-5","article-title":"Evolution of the novel coronavirus from the ongoing wuhan outbreak and modeling of its spike protein for risk of human transmission","volume":"63","author":"Xu","year":"2020","journal-title":"Science China Life Sciences"},{"key":"bib37","doi-asserted-by":"publisher","first-page":"6532","DOI":"10.1128\/AAC.01043-16","article-title":"Identification of nafamostat as a potent inhibitor of middle east respiratory syndrome coronavirus S protein-mediated membrane fusion using the split-protein-based cell-cell fusion assay","volume":"60","author":"Yamamoto","year":"2016","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"bib38","doi-asserted-by":"publisher","DOI":"10.1101\/2020.02.19.956946","article-title":"Structural basis for the recognition of the 2019-nCoV by human ACE2","volume-title":"bioRxiv","author":"Yan","year":"2020"},{"key":"bib39","doi-asserted-by":"publisher","DOI":"10.1038\/srep07027","article-title":"Angiotensin-converting enzyme 2 (ACE2) mediates influenza H7N9 virus-induced acute lung injury","volume":"4","author":"Yang","year":"2015","journal-title":"Scientific Reports"},{"key":"bib40","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1007\/s00134-020-05985-9","article-title":"Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target","volume":"46","author":"Zhang","year":"2020","journal-title":"Intensive Care Medicine"},{"key":"bib41","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-020-0360-5","article-title":"COVID-19 and the cardiovascular system","volume":"395","author":"Zheng","year":"2020","journal-title":"Nature Reviews Cardiology"},{"key":"bib42","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"}],"container-title":["eLife"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/cdn.elifesciences.org\/articles\/57278\/elife-57278-v6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/cdn.elifesciences.org\/articles\/57278\/elife-57278-v6.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/elifesciences.org\/articles\/57278","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T21:09:10Z","timestamp":1697058550000},"score":1,"resource":{"primary":{"URL":"https:\/\/elifesciences.org\/articles\/57278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,6]]},"references-count":42,"alternative-id":["10.7554\/eLife.57278"],"URL":"https:\/\/doi.org\/10.7554\/elife.57278","archive":["CLOCKSS"],"relation":{"has-review":[{"id-type":"doi","id":"10.7554\/eLife.57278.sa1","asserted-by":"object"},{"id-type":"doi","id":"10.7554\/eLife.57278.sa2","asserted-by":"object"}]},"ISSN":["2050-084X"],"issn-type":[{"value":"2050-084X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,6]]},"article-number":"e57278"}}